KOSDAQ Biotech Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
02:34
Aug 20
Aug 20
Avoid broad KOSDAQ biotech due to risks.
The Korean biotech sector is experiencing severe decoupling and high risk. While a few companies succeeding in technology exports (like Alteogen) are rising, many others face delisting risks and capital reductions as the government weeds out weak firms, making the broad sector dangerous.
MED
07:00
Aug 09
Aug 09
Biotech is the most promising KOSDAQ sector.
The KOSDAQ market has bottomed, and biotech is the most promising sector. Companies with proven license-out track records, validated platforms, and solid cash flow offer good opportunities, especially as ETF inflows can lift the broader sector.
HIGH
02:00
Jun 27
Jun 27
Short-term KOSDAQ biotech trading opportunity.
Korean biotech (KOSDAQ) has shown short-term pops and can be used as a tactical trading vehicle when large-cap semis take a breather. The sector is not a long-term investment but provides daily trading chances amid the broader market choppiness.
MED
12:51
Jan 26
Jan 26
KOSDAQ 3,000 needs four sectors
KOSDAQ is roughly 40% biotech, 19% semiconductor equipment, 14% battery, and 8% robots. For KOSDAQ to reach 3,000, these four sectors must rise. In a supply-demand market, valuation is less important than flows, so focus on top market-cap names in these sectors.
HIGH
12:51
Jan 26
Jan 26
KOSDAQ biotech rebound favors top names
KOSDAQ biotech is structurally attractive because it is the largest KOSDAQ sector and is benefiting from fund inflows. Alteogen-specific bad news caused indiscriminate ETF selling in peers, creating oversold rebound opportunities in top market-cap biotech names with less volume spike than Alteogen. ABL Bio is specifically favored.
MED
13:50
Jan 23
Jan 23
Bio is best KOSDAQ policy play.
KOSDAQ policy support hits bio first because biotech is the largest KOSDAQ sector and institutions are buying. Unlike batteries, bio lacks visible near-term numbers, so global big-pharma deals and pipeline stories can keep adding upside; investors should not sell into the policy-driven rebound.
HIGH
00:50
Jan 21
Jan 21
Buy KOSDAQ biotech after Samsung earnings.
Korean biotech may start moving after Samsung Electronics reports earnings. Historically, January-end KOSDAQ strength and biotech rallies follow the JP Morgan Healthcare Conference, with a second catalyst from AAC in March-April, and stocks with strong holders are already showing resilient supply.
MED
00:27
Jan 12
Jan 12
JPM healthcare conference may lift KOSDAQ biotech.
The JPMorgan Healthcare Conference is a key catalyst this week. If large pharma or biotech announcements emerge, the speaker expects momentum could return to KOSDAQ biotech and help the broader KOSDAQ, which has lagged due to prior weakness in bio, robots, cosmetics, and entertainment.
MED
23:34
Jan 01
Jan 01
KOSDAQ biotech can lead on patents
Large drugs are losing patents, and Korea has prepared well for the resulting opportunity, so biotech should be a leading KOSDAQ sector in 2026.
MED
About KOSDAQ Biotech Investor Commentary
Across the available history and selected sources, Buzzberg tracks KOSDAQ Biotech across 2 sources: 6 bullish vs 0 bearish calls from 9 authors. Historical directional balance: 67% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 9 total trade ideas tracked. Latest voices: Park Hyun-ji, Lee Young-hoon, Park Myung-seok.